@article {Marthin00301-2021, author = {June K. Marthin and Jane S. Lucas and Mieke Boon and Carmen Casaulta and Suzanne Crowley and Damien M.S. Destouches and Ernst Eber and Amparo Escribano and Eric Haarman and Claire Hogg and Bernard Maitre and Gemma Marsh and Vendula Martinu and Antonio Moreno-Gald{\'o} and Huda Mussaffi and Heymut Omran and Petr Pohunek and Bernhard Rindlisbacher and Phil Robinson and Deborah Snijders and Woolf T. Walker and Panayiotis Yiallouros and Helle Krogh Johansen and Kim G. Nielsen}, title = {International BEAT-PCD consensus statement for infection prevention and control for primary ciliary dyskinesia in collaboration with ERN-LUNG PCD Core Network and patient representatives}, volume = {7}, number = {3}, elocation-id = {00301-2021}, year = {2021}, doi = {10.1183/23120541.00301-2021}, publisher = {European Respiratory Society}, abstract = {Introduction In primary ciliary dyskinesia (PCD) impaired mucociliary clearance leads to recurrent airway infections and progressive lung destruction, and concern over chronic airway infection and patient-to-patient transmission is considerable. So far, there has been no defined consensus on how to control infection across centres caring for patients with PCD. Within the BEAT-PCD network, COST Action and ERS CRC together with the ERN-Lung PCD core a first initiative has now been taken towards creating such a consensus statement.Methods A multidisciplinary international PCD expert panel was set up to create a consensus statement for infection prevention and control (IP\&C) for PCD, covering diagnostic microbiology, infection prevention for specific pathogens considered indicated for treatment and segregation aspects. Using a modified Delphi process, consensus to a statement demanded at least 80\% agreement within the PCD expert panel group. Patient organisation representatives were involved throughout the process.Results We present a consensus statement on 20 IP\&C statements for PCD including suggested actions for microbiological identification, indications for treatment of Pseudomonas aeruginosa, Burkholderia cepacia and nontuberculous mycobacteria and suggested segregation aspects aimed to minimise patient-to-patient transmission of infections whether in-hospital, in PCD clinics or wards, or out of hospital at meetings between people with PCD. The statement also includes segregation aspects adapted to the current coronavirus disease 2019 (COVID-19) pandemic.Conclusion The first ever international consensus statement on IP\&C intended specifically for PCD is presented and is targeted at clinicians managing paediatric and adult patients with PCD, microbiologists, patient organisations and not least the patients and their families.For the first time ever, an international consensus statement for infection prevention and control in PCD is presented. A total of 20 statements were developed in a collaboration of BEAT-PCD, COST Action, ERS CRC and ERN-LUNG PCD Core Network. https://bit.ly/3yuahKt}, URL = {https://openres.ersjournals.com/content/7/3/00301-2021}, eprint = {https://openres.ersjournals.com/content/7/3/00301-2021.full.pdf}, journal = {ERJ Open Research} }